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Introduction: Current methods to determine HER2 (human epidermal growth factor receptor
2) status are affected by reproducibility issues and do not reliably predict benefit from anti-
HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast
cancer (BC) patients who will respond to anti-HER2 treatments.
Methods: Using selected reaction monitoring mass spectrometry (SRM-MS), we quantified
HER2 protein levels in formalin-fixed, paraffin-embedded (FFPE) tissue samples that had
been classified as HER2 0, 1þ, 2þ or 3þ by immunohistochemistry (IHC). Receiver operator
curve (ROC) analysis was conducted to obtain optimal HER2 protein expression thresholdsrowth factor receptor 2; SRM-MS, selected reaction monitoring mass spectrometry; ROC,
pectrometry; CEP17, centromere 17; DM, double minutes; HSR, homogeneously staining re-
HR, hormone receptor; ADCC, antibody-dependent cell cytotoxicity.
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In situ hybridizationpredictive of HER2 status (by standard IHC or in situ hybridization [ISH]) and of survival
benefit after anti-HER2 therapy.
Results: Absolute HER2 amol/mg levels were significantly correlated with both HER2 IHC and
amplification status by ISH (p < 0.0001). A HER2 threshold of 740 amol/mg showed an agree-
ment rate of 94% with IHC and ISH standard HER2 testing (p < 0.0001). Discordant cases
(SRM-MS-negative/ISH-positive) showed a characteristic amplification pattern known as
double minutes. HER2 levels >2200 amol/mg were significantly associated with longer
disease-free survival (DFS) and overall survival (OS) in an adjuvant setting and with
longer OS in a metastatic setting.
Conclusion: Quantitative HER2 measurement by SRM-MS is superior to IHC and ISH in pre-
dicting outcome after treatment with anti-HER2 therapy.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction of targeted proteins in patient-derived formalin fixed, paraffinGene amplification or protein overexpression of the human
epidermal growth factor receptor type 2 (HER2) has been re-
ported in w20% of invasive breast cancer (BC) and is usually
associated with worse prognosis (Slamon et al., 1987, 1989).
The monoclonal antibody trastuzumab has dramatically
increased survival in patients with HER2-overexpressing met-
astatic disease (Hudis, 2007; Slamon et al., 2001) and has often
proved curative when used in combination with chemo-
therapy in the adjuvant setting (Joensuu et al., 2006; Piccart-
Gebhart et al., 2005; Romond et al., 2005; Smith et al., 2007).
The benchmarks for defining tumors as HER2-positive
(HER2þ) is the presence of protein overexpression (3þ) by
immunohistochemistry (IHC) or gene amplification by in situ
hybridization (ISH), according to current clinical guidelines
(Wolff et al., 2013). However, considerable controversy still ex-
ists regarding the accuracy, reliability, and inter-observer
variability of these methods. Studies in patients treated with
trastuzumab indicate that neither test is a perfect predictor
of response to trastuzumab (Dowsett et al., 2009; Perez et al.,
2010). It is estimated that up to 20% of tumors initially classi-
fied as HER2þ by IHC are actually false-positives (Paik et al.,
2002; Perez et al., 2006; Roche et al., 2002), and an estimated
1.1%e11.5% of HER2-negative (HER2-) patients by IHC that
never received anti-HER2 therapy harbor HER2 gene amplifi-
cation by ISH (Hanna et al., 2014). False positives HER2 results
increase treatment costs (trastuzumab costs $50,000/person/
year in the US) and expose patients to a likely ineffective ther-
apy; false negative results deny patients the potential benefits
of anti-HER2 therapy.
It is widely accepted that the levels of HER2 are not homo-
geneous among the HER2þ population defined by conven-
tional semi-quantitative methods such as IHC. Tests capable
of absolute quantitation of HER-family protein expression
have demonstrated that HER2 protein expression can vary
up to 100 fold and that tumors with high HER2 expression
are more likely to benefit from anti-HER2 therapy in the neo-
adjuvant (Cheng et al., 2014; Denkert et al., 2013), adjuvant
(Pogue-Geile et al., 2013), and metastatic (Montemurro et al.,
2014) settings.
We have recently developed a mass spectrometry (MS)-
based proteomic BC panel tomeasure the absolute abundanceembedded (FFPE) tissue for use in clinical decision-making.
The reliability of this assay for protein analysis has been
demonstrated (Hembrough et al., 2012), however, its clinical
utility for patient stratification, choice of therapy, and drug
resistance prediction is still being evaluated. In this work,
we tested this methodology’s ability to predict HER2 status
as determined by standard IHC/ISH in a panel of breast tu-
mors. We also assessed the value HER2 quantitation by MS
for predicting disease-free survival (DFS) or overall survival
(OS) of patients with HER2-positive BC after treatment with
anti-HER2 therapy.2. Material and methods
2.1. Patients and tissue samples
Samples of histologically confirmed invasive BC diagnosed at
Vall d’Hebron University Hospital (Barcelona, Spain) were
retrospectively identified by one study pathologist (CA) be-
tween 1997 and 2013. Sampleswere selected to ensure a repre-
sentative number of HER2- and HER2þ samples and to include
cases treated with trastuzumab to enable survival analyses in
a subset of patients. Sample selection criteria were: known
HER2 status tested in the setting of the routine surgical pathol-
ogy laboratory and available FFPE tumor sample for SRM-MS
analysis. For survival analyses, samples with available data
on type of anti-HER2 treatment and outcome were included.
The study was approved by the hospital ethical committee,
including a waiver of consent for the use of archival material
for research.
2.2. HER2 standard testing (combined IHC/ISH)
HER2 status was retrieved from hospital Vall d’Hebron pathol-
ogy laboratory reports (HER2 local). The diagnostic algorithm
for HER2 testing used was IHC on all cases and ISH assays
done on all IHC2þ equivocal cases (per ASCO/CAP guidelines).
Protein expressionwas determined in paraffin-embedded sec-
tions using the 4B5 (Ventana Medical Systems, Tucson, AZ)
antibody. HER2 amplification was determined using silver-
enhanced ISH (SISH) and carried out with an INFORM HER2
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and scored according to both the 2007 ASCO/CAP guidelines
and the 2013 update of these guidelines.
For the purpose of this study, and to exclude any possibility
of heterogeneity in the tumor with respect to HER2 expres-
sion, IHC and ISH were repeated on all HER2 3þ patients
with available tissue samples and on discordant cases on
the same tissue block of the resection specimen sent for
SRM-MS testing (HER2 central). Central testing was performed
using IHC (HercepTest) and FISH (HER2 FISH pharmDx Kit) or
SISH (INFORM HER2 Dual ISH DNA Probe Assay, Ventana) ac-
cording to ISO15189 standards and interpreted following the
most recent ASCO/CAP guidelines. HER2 gene status was
assessed by two pathologists (CA and VP) blindly scoring 30
nuclei for the number of HER2 and centromere 17 (CEP17) sig-
nals in each cell. TheHER2/CEP17 probe signal ratio was deter-
mined and the patterns of HER2 amplification were analyzed
in those cases with HER2/CEP17 ratio 2. Samples with >70%
of the cells with double minutes (DM, small dispersed dots
distributed through the nucleus) or homogeneously staining
regions (HSR, tightly clustered dots in discrete regions of the
nucleus) patterns were classified accordingly. Cases with
both HSR and DM patterns in the same sample were classified
as mixed (MIX).2.3. HER2 quantification by SRM-MS
HER2 protein was quantitated by SRM-MS as previously
described (Hembrough et al., 2013). Briefly, tissue sectionsFigure 1 e Breast cancer tumor samples selected for analysis. SRM, select
hybridization; AMPL, amplified.(10 mM) were cut from FFPE blocks, placed onto DIRECTOR
microdissection slides, deparaffinized and stained with he-
matoxylin. Tumor areas were marked by a board-certified
pathologist and a cumulative area of a 12 mm2 (frommultiple
sections of a single tumor if necessary) containing approxi-
mately 45,000 malignant cells was microdissected from each
tumor and then solubilized to tryptic peptides using Liquid
Tissue technology. This tryptic peptide mixture was then
subjected to SRM-MS analysis using stable isotope-labeled in-
ternal standard for accurate quantitation of analytical targets.
The peptide that was chosen for HER2 was ELVSEFSR (located
in the intracellular region of HER2, aa 971e978). This peptide is
unique to HER2 and has been reported to be the best sequence
for SRM in FFPE tissue (Schoenherr et al., 2012; Steiner et al.,
2015). On-column injection resulted in 1 mg (w4000 cells) of
solubilized tissue and 5 fmol of internal standard measured
by microBCA (ThermoFisher Scientific, San Jose, CA). Instru-
mental analyses were performed on TSQ series (Vantage or
Quantiva) triple quadrupole mass spectrometer (Thermo Sci-
entific, San Jose, CA). The MS and chromatography conditions
have been previously described (Catenacci et al., 2014).2.4. Statistical methods
To select a SRM-MS threshold for stratifying tumors into
HER2þ and HER2-, receiver operating characteristic (ROC)
curves were constructed by computing the sensitivity and
specificity of increasing quantities of HER2 (by SRM-MS) in
predicting HER2 positivity (by combined IHC/ISH). Differencesed reaction monitoring; IHC, immunohistochemistry; ISH, in situ
Table 1 e Characteristics of 270 clinical samples used in the study.
Characteristics N %
Patient specimen
Surgical resection 255 95
Diagnostic core biopsy 6 2
Recurrent disease 9 3
Histological grade
G1 16 6
G2 112 41
G3 134 50
Unknown 8 3
Pathological stage T
TxeT1 143 53
T2eT4 123 46
Unknown 4 1
Pathological stage N
NxeN0 147 54
N1eN3 119 44
Unknown 4 1
Hormone receptor status (HR)
Negative 47 17
Positive 223 83
HER2 overexpression by IHC
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ISH subgroups were analyzed by using KruskaleWallis tests.
The Spearman rank correlation coefficient (Spearman r) was
used to describe the relationship between the HER2 protein
levels by SRM-MS, HER2 gene copy number (GCN) and HER2/
CEP17 ratio by central ISH. Among patients who had received
anti-HER2 therapy, ROC analysis was used to establish an
optimal cutoff for HER2 levels (by SRM-MS, HER2/CEP17 ratio
and HER2 GCN) that would predict disease-free, progression-
free, and overall survival in the adjuvant and metastatic set-
tings. Chi-square test and Fisher’s exact test were used to
determine the nature of the associations between optimal cut-
off points and clinicopathological parameters. Survival was
modeled using the KaplaneMeier curves, and the significance
of differences between these curves was determined using
hazard ratio (HR) and its confidence interval of 95%, and the
p-value obtained by the log-rank test. Multivariate survival
analysis was performed using the Cox proportional hazards
model adjusted for hormone receptor status, tumor stage,
lymph node status and HER2 SRM levels. Results were consid-
ered significant when p-values ( p) were less than 0.05. Statis-
tical analyses were conducted using R software, version 3.0.3.
0 39 14
1 49 18
2 49 18
3 133 49
Table 2 e Concordance between SRM-MS and local and central
combined IHC/ISH.
HER2 Status
(IHC/ISH)
n SRM-MS Agreement,
n (%)
Local Negative 135 130 (96%)
Positive 142 125 (88%)
Central Negative 144 137 (95%)
Positive 133 123 (92%)
Local, local HER2 testing result; Central, central HER2 re-testing re-
sults; SRM-MS, selected reaction monitoring mass spectrometry.
IHC, Immunohistochemistry; ISH, in situ hybridization.3. Results
3.1. Patients and tissue samples
We identified 326 samples, of which 277 (85%) were suitable
for SRM-MS analysis. Forty-nine samples were discarded for
lack of sufficient tumor tissue for SRM-MS. Of the 277 study
samples, 270 were FFPE breast cancer samples and 7 were
cell lines (Figure 1, Table 1 and Supplementary Table 1). Pa-
tient specimens were obtainedmainly from surgical resection
(n¼ 255), and a small part from diagnostic core biopsies (n¼ 6)
or sampling of recurrent disease (n ¼ 9). The study series
included 41 HER2 0þ, 49 HER2 1þ, 51 HER2 2þ, and 136 HER2
3þ assessed by IHC. Of the 142 samples classified as HER2þ
by combined IHC/ISH approach, 95 were included in the sur-
vival analysis (Supplementary Table 2). Forty-seven were
excluded due to the following: twenty-five were replicated
samples from the same patients; seven were lost to follow
up; five were still under treatment at the time of the analysis;
three received trastuzumab after 12 months from diagnosis
(atypical adjuvant); three were cell lines; two had a bilateral
invasive breast carcinoma; and two had received trastuzumab
as neoadjuvant treatment. Sixty-eight patients received adju-
vant chemotherapy in combination with trastuzumab alone
(76%, n ¼ 52) or combined with another anti-HER2 agent
(24%, lapatinib, n ¼ 6 and pertuzumab, n ¼ 10). Twenty-
seven received anti-HER2 therapy in the metastatic setting.
Trastuzumab alone was the preferred anti-HER2 treatment
(70%, n ¼ 19), followed by trastuzumab combined with
another anti-HER2 (22%, pertuzumab, n ¼ 5; lapatinib, n ¼ 1),
T-DM1 (4%, n ¼ 1), and T-DM1 plus pertuzumab (4%, n ¼ 1).
3.2. SRM-MS versus standard IHC/ISH
The average HER2 protein level in the analyzed dataset
(n ¼ 277) as measured by SRM-MS was 2217.9 amol/mg(median: 643.5; sd: 3299.4; range: 0 to 17,446.7). Absolute
HER2 amol/mg levels increased with increasing IHC scores
with averages values of 189.1, 259.9, 406.7 and 4214.1 in
HER2 IHC 0þ, 1þ, 2þ, and 3þ, respectively (p < 0.001, Krus-
kaleWallis rank sum test) (Supplementary Table 3). Samples
scored as HER2 IHC3þ expressed the widest dynamic range
of HER2 protein levels as quantified by SRM-MS (range:
163.7e17,446.7 amol/mg). When correlated with amplification
status, HER2 protein levels were also substantially higher in
ISH-amplified (mean: 4151.2 amol/mg; sd: 3682.1; range:
272.8e17,446.7) than non-amplified samples (mean:
383.8 amol/mg; sd: 339.1; range: 0e1748.0; p < 0.001, Wilcoxon
test, Supplementary Table 4). In our study we analyzed sam-
ples collected from 1997 to 2013. Although the SRM-MS is an
epitope-independent technology and its robustness has been
proven (Catenacci et al., 2014), we addressed the stability of
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values did not differ significantly with age of the tissue blocks
thus supporting the validity of results generated using sam-
ples collected over a period of many years (Supplementary
Table 5).
Per ROC analysis, the SRM-MS threshold that best corre-
lated with HER2 status by combined local IHC/ISH was
740 amol/mg (area under the ROC curve: 0.963). When strati-
fied according to this threshold, 130 samples (47%) were clas-
sified as overexpressors and 147 (53%) as non-
overexpressors. The overall percent agreement between
SRM-MS and combined local IHC/ISH was 92% (255 of 277).
The percent positive agreement was 88% (125 of 142), and
the percent negative agreement was 96% (130 of 135) (Table
2). HER2 status by SRM-MS for 277 breast cancer samples
that had been previously scored by local IHC testing and sub-
sequently evaluated by ISH reflex central testing are shown
in Figure 2. In the HER2 IHC negative group (0þ and 1þ,
n¼ 90), 86 samples (96%) were correctly classified as negative
and 4 (4%) as positive by SRM-MS. After central retest, none
of these 4 positive samples showed HER2 amplification. In
the HER2 IHC equivocal group (2þ, n ¼ 51), 47 (92%) and 4
(8%) samples were classified as negative and positive by
SRM-MS, respectively. Three of these 4 SRM-MS-positive
samples were HER2 amplified (the non-amplified discordant
sample was the ZR75-1 cell line). Three out of 47 samples
(6%) classified as negative by SRM-MS showed HER2 gene
amplification.
In the HER2 IHC positive group (3þ, n ¼ 136), 122 samples
(90%) were correctly classified as positive whereas 14 samples
(10%) as negative by SRM-MS. HER2 gene amplification was
centrally confirmed in 111 (98%) of the 113 evaluable IHC3þ/
SRM-MS-positive samples (not amplified, n¼ 2; data not avail-
able, n ¼ 9). Among IHC3þ/SRM-MS-negative (n ¼ 14), seven
harbored HER2 gene amplification. Overall agreement after
central retest was 94% (260 of 277), the percent positive agree-
ment was 92% (123 of 133), and the percent negative agree-
ment was 95% (137 of 144) (Table 2). Details of the discordant
samples between SRM-MS and combined IHC/ISH are shown
in Supplementary Table 6.Figure 2 e HER2 selected reaction monitoring-mass spectrometry (SRM-M
(0D, 1D), equivocal (2D) or positive (3D) with subsequent ISH central re
Discordant cases are highlighted. L, negative; D, positive; na, not assesse3.3. Relationship between HER2 gene amplification
pattern and HER2 protein levels
After central retest, 6% (17/277) of samples remained discor-
dant. The 7 SRM-MS-positive/ISH-negative samples showed
absolute HER2 protein levels below the average dataset value
(2217.9 amol/mg) and very close to the 740 amol/mg threshold
distinguishing overexpressors from non-overexpressors. The
remaining 10 samples showed low protein levels
(<740 amol/mg) despite HER2 gene amplification. When strati-
fied by HER2 amplification pattern, 8 of 10 samples had pat-
terns involving extrachromosomal circles of DNA known as
DM and the remaining 2 showed a mixed amplification
pattern. No significant differences in HER2/CEP17 ratios were
evident (data not shown).
We therefore investigated whether, in the presence of
HER2 gene amplification, the levels of HER2 protein in the tu-
mor tissue may be influenced by its amplification pattern
rather than the levels of gene amplification itself. To test
this hypothesis, we correlated HER2 expression by SRM-MS
with HER2 GCN, HER2/CEP17 ratio and pattern of amplification
(HSR, DM, MIX) in HER2 IHC 2þ (n ¼ 6) and IHC3þ (n ¼ 117)
cases amplified by central ISH. The mean HER2 protein SRM-
MS level was 4047.1 amol/mg (sd: 3508.9; range:
272.8e17,446.7). Mean HER2 GCN was 14.0 (sd: 4.2; range:
5.2e22.2). Mean HER2/CEP17 ratio was 7.2 (sd: 2.5; range:
2.1e15.0) (Supplementary Table 7). HER2 SRM-MS levels
showed weak positive correlations with HER2 GCN (Spearman
r ¼ 0.44; p < 0.001) and HER2/CEP17 ratio (Spearman r ¼ 0.31;
p < 0.001) (Figure 3). Forty-one percent of samples (n ¼ 50) had
HSR patterns, 37% (n ¼ 46) had DM patterns and 22% (n ¼ 27)
were mixed. Average HER2 protein levels were significantly
higher in tumors amplified with HSR (mean: 5462.9; sd:
3368.4; range: 1099.3e17,446.7) compared to those with DM
(mean: 2176.4; sd: 1908.1; range: 272.8e8070.0)
(Supplementary Table 8).
DM amplification patterns were present in 80% (8/10) of
samples with low HER2 protein levels; only 34% (38/113) of
samples with high HER2 protein levels had DM patterns
(Supplementary Table 9).S) results for 277 breast cancers previously classified as IHC negative
testing results. SRM-MS-positive [ HER2 protein>740 amol/mg.
d.
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ROC analysis of patients treated with anti-HER2 therapy
(n ¼ 95) resulted in cutoff values of 2200 amol/mg for HER2
SRM-MS, 6.4 for HER2/CEP17 ratio and 12.5 for HER2 GCN
(Supplementary Table 10). The 2200 amol/mg HER2 SRM-MS
cutoff outperformed the 740 cutoff in predicting DFS and OS
(Supplementary Table 11) and was used for survival analyses.Figure 3 e Correlation between the HER2 protein expression by SRM-MS
indicates HER2 SRM-MS 740 amol/mg threshold. Spearman rank correlati
and HER2 GCN (r, 0.44; p< 0.001) and SRM-MS and HER2/CEP17 (r
shown. Red circle, homogeneously staining regions (HSR); blue circle, dou
images of protein expression by IHC and amplification patterns by ISH arThe correlations between the optimal HER2 SRM-MS, HER2/
CEP17 ratio and HER2 GCN cutoffs for survival and clin-
icepathological parameters are shown in Supplementary
Table 12 and 13. Patients showing HER2 levels by SRM-MS
above the threshold of 2200 amol/mg (n¼ 58, 61%)were defined
as super-expressors. In the adjuvant setting (n ¼ 68), super-
expressors had a statistically significantly better outcome
than non-super-expressors (Figure 4). The number ofand HER2/CEP17 ratio (A), and HER2 GCN (B). Dotted gray line
on coefficient was used to describe the relationship between SRM-MS
, 0.31; p< 0.001). Pattern of amplification by in situ hybridization is
ble minutes (DM); orange circle, Mixed pattern. c, Representative
e shown together with SRM-MS protein levels.
Figure 4 e KaplaneMeier curves for disease-free survival (AeC) and overall survival (DeF) according to HER2 protein expression by SRM-MS
(A,D), HER2/CEP17 ratio (B,E) and HER2 gene copy number (GCN) (C,F) in patients treated with anti-HER2 in the adjuvant setting. Optimal
cutoff values were determined by receiver operating characteristic (ROC) analysis. Disease-free survival and overall survival were superior for the
group of patients with high HER protein levels (>2200). HR, hazard ratio; HER2 Ratio, HER2/CEP17 ratio; CI, confidence interval.
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to 9 events observed in tumors with HER2 levels below
2200 amol/mg (HR ¼ 0.22, 95% CI 0.06e0.81, log rank
p ¼ 0.013). Differences in DFS were even greater between re-
fractory patients (relapse within 24 months) and patients
without relapse or recurrent disease within 24 months
(OR ¼ 23, 95% CI, 1.26e434.86, p 0.003).
Similar results were observed for OS. None of the super-
expressors died of the disease compared to 7 patients whose
tumors were below 2200 amol/mg (HR ¼ na, p 0.001). Neither
HER2/CEP17 ratio nor HER2 GCN was predictive of longer DFS
or OS in the adjuvant setting (Figure 4).
In the first-linemetastatic setting (n¼ 27), 18 (67%) patients
were classified as super-expressors. Median OS was signifi-
cantly longer in super-expressors (7.84; 95% CI: 5.23 to NA)
as compared to non-super-expressors (2.91; 95% CI: 1.61 to
NA), (HR ¼ 0.20; 95% CI: 0.07 to 0.57; p < 0.001), (Figure 5). In
this setting, HER2 GCN (HR ¼ 0.15; p ¼ 0.001) and, to a lesser
extent, HER2/CEP17 ratio (HR ¼ 0.32; p ¼ 0.050) were also pre-
dictive of a better OS. No significant correlations were found
between HER2 protein levels or gene status and PFS, likely
due to the fact that all but two patients relapsed during follow
up. When looking at relapse within 24 months, nine of 18(50%) super-expressors were refractory to anti-HER2 therapy
compared to all (n ¼ 9) patients with HER2 lower than 2200.
No correlation was found between HER2 pattern of amplifica-
tion and survival in both adjuvant and metastatic series
(Supplemental Table 14).
In the multivariate model which includes hormone recep-
tor status, tumor size (T) and presence of lymph-node metas-
tases (N), HER2 levels by SRM-MS independently predictedDFS
in the adjuvant setting (HR ¼ 0.25; 95% CI: 0.06 to 0.96;
p ¼ 0.044) (Table 3). The model could not be run for OS due
to lack of events in the HER2 super-expressor group.4. Discussion
This report demonstrates the application of a MS-based
method to objectively quantify HER2 protein in FFPE clinical
tissue samples from BC patients. We showed that within
IHC-positive (3þ) ISH-amplified tumors, a wide dynamic range
of HER2 protein expression is found and the subgroup of tu-
mors with the highest levels benefitted most from HER2 inhi-
bition. Our findings suggest that quantitative HER2
measurement is superior to gene amplification levels in
Figure 5 e KaplaneMeier curves for progression-free survival (AeC) and overall survival (DeF) according to HER2 protein expression by SRM-
MS (A,D), HER2/CEP17 ratio (B,E) and HER2 gene copy number (GCN) (C,F) in patients treated with anti-HER2 in the metastatic setting.
HR, hazard ratio; HER2 Ratio, HER2/CEP17 ratio; CI, confidence interval.
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treatment in both adjuvant and metastatic settings.
The ASCO/CAP guidelines (Wolff et al., 2013) recommend
initial HER2 screening of all BC, followed by ISH for samples
with equivocal staining; the results of these tests determine
a patient’s eligibility for trastuzumab. However, lack of
concordance between IHC and ISH (IHC-negative/ISH-posi-
tive) occurs in up to 11.5% of cases (Hanna et al., 2014). Our
findings suggest that these conflicting results may be only
marginally due to pre-analytic (fixation affects antibody sensi-
tivity), analytic (limited dynamic range of chromogenic IHC,
different antibodies used), or post-analytic (subjectivity inTable 3eMultivariate analyses of disease-free survival (DFS) in the
68 patients included in the adjuvant series.
DFS HR CI95%(HR) p-value
Hazard Hormone receptor positiveð Þ
Hazard Hormone receptor negativeð Þ
0.19 0.05e0.70 0.012
HazardðTXT1Þ
HazardðT2T4Þ 0.20 0.05e0.73 0.015
HazardðNXN0Þ
HazardðN1N3Þ
1.19 0.36e3.94 0.777
HazardðHER22200Þ
HazardðHER2<2200Þ
0.24 0.06e0.96 0.044interpretation of the results) factors (Camp et al., 2002;
Rimm, 2006). In fact, despite the high correlation observed
with IHC score or gene amplification detected by ISH, we
found that approximately 10% of HER2-amplified breast tu-
mors expressed very low amounts of HER2 protein; all of these
discordant cases were associated with a gene amplification
pattern known as DM.
Evidence indicates that the amplification of genes in DM
may result in a dynamic regulation of gene expression and
resistance to EGFR TKIs for EGFRvIII-positive glioblastomas
(Nathanson et al., 2014). Conversely, data from our group did
not find any significant correlation between amplification of
HER2 in DM content and sensitivity to anti-HER2 therapy
(Vicario et al., 2015). Quantitative HER2 protein analysis, how-
ever, may identify a subset of HER2 tumors amplified in DM
with low HER2 expression that are less sensitive to anti-
HER2 treatment.
Based on our analysis, patients expressing greater than
740 amol/mg of HER2 should receive anti-HER2 treatment, as
this was the optimal threshold that correlated with standard
IHC/ISH. However, the most meaningful endpoint of HER2
testing is not prediction of HER2 status by IHC or ISH, but
outcome after HER2-targeted therapies. Using quantitative
HER2 measurement, we found that patients whose tumors
expressed HER2 protein level >2200 amol/mg) benefitted
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 3 8e1 4 7146more from anti-HER2 therapy than patients with lower HER2
expression levels. Strikingly, relapse within 24 months was
observed in 21% of patients with HER2 expression levels below
2200 amol/mg and none of the super-expressors progressed to
therapy in this period of time. One possible explanation is that
tumors with high levels of HER2 are enriched with “true”
HER2-dependent disease and therefore potentially more sus-
ceptible to HER2 blockade (Montemurro et al., 2014). Another
explanation is that the more HER2 receptors are present in
themembrane of tumor cells, themoremolecules of trastuzu-
mab (or other anti-HER2 antibodies) can bind and prime
antibody-dependent cell cytotoxicity (ADCC). A direct correla-
tion between HER2 levels and ADCC has been reported in pre-
clinical models (Scaltriti et al., 2009).
Our findings should be considered in light of certain limita-
tions. The number of patients included in this proof-of-
concept study is small and the cutoff point of 2200 amol/mg
was based on the survival outcomes in patients whose tissues
were selected for the analysis. This cutoff needs to be vali-
dated in a larger, independent set of patients. Also, survival
analyses included only individuals who had received anti-
HER2 treatment. Prospective trials will be needed to address
the question of whether varying levels of HER2 positivity are
truly predictive of response in all BC patients. Studies are un-
derway to validate the cut-off in an expanded BC cohort.5. Conclusions
HER2 protein quantitation by SRM-MS in FFPE tissues is pre-
dictive of response to anti-HER2 therapy and survival in
HER2-positive (by standard IHC/FISH) BC patients. Moreover,
thismethodologymay allow the identification of FISH positive
cases that express low amounts of HER2 and respond poorly to
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